Aurinia Pharmaceuticals Inc

9 oct. 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are advancing, continuing their upward trajectory since Thursday's close, amid generally positive market conditions in the biotechnology sector.

8 oct. 2026, 20:01 UTC

Aurinia Pharmaceuticals Inc shares are advancing, recovering from a mid-morning dip to near the day's high, following a higher trend since Wednesday's close.

7 oct. 2026, 19:45 UTC

Aurinia Pharmaceuticals Inc is trading higher, reaching a peak earlier today, but remains below its 20-day moving average after six consecutive lower closes.

6 oct. 2026, 23:10 UTC

Aurinia Pharmaceuticals Inc. declines in after-market trading, closing at its lowest point of the day and remaining below its 20-day moving average.

2 oct. 2026, 20:07 UTC

Aurinia Pharmaceuticals Inc shares fell, marking a fifth consecutive session of lower closes, and remain significantly below their 20-day moving average.

1 oct. 2026, 22:50 UTC

Declining in after-market, Aurinia marks fourth straight session lower.

29 sept. 2026, 20:07 UTC

Aurinia Pharmaceuticals Inc shares fell, reversing from an earlier rise, and are currently positioned around the midpoint of their one-month trading range.

24 sept. 2026, 20:03 UTC

Aurinia Pharmaceuticals Inc is trading higher amid gains in the Biotechnology sector, remaining above its 20-day moving average and within its one-month range.

23 sept. 2026, 20:07 UTC

Aurinia Pharmaceuticals Inc shares fell sharply, continuing a decline from Tuesday's close amid a broader market trend of lower performance.

22 sept. 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc is declining in after-market trading, influenced by broader market pressures and an unexpected contraction in the U.S. Richmond Fed Manufacturing Index.

16 sept. 2026, 19:22 UTC

Aurinia Pharmaceuticals Inc shares are significantly higher after reporting a substantial increase in quarterly revenue and a rise in net income from LUPKYNIS sales.

15 sept. 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc. shares are trading lower amid broader market sentiment influenced by anticipated Federal Reserve rate hikes and rising Treasury yields.

14 sept. 2026, 20:07 UTC

Aurinia Pharmaceuticals shares are higher amid market volatility and inflation concerns ahead of the Federal Reserve's interest rate decision.

10 sept. 2026, 20:06 UTC

Aurinia Pharmaceuticals shares are lower today, influenced by broader market declines amid macroeconomic factors, including the European Central Bank's interest rate hike.

9 sept. 2026, 20:41 UTC

Aurinia Pharmaceuticals Inc shares are higher in after-market trading, showing increased investor interest despite no specific company news, remaining above their 20-day moving average.

8 sept. 2026, 23:36 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

1 sept. 2026, 20:08 UTC

Aurinia Pharmaceuticals is declining amid broader market losses and rising inflation concerns, with no specific company news identified to explain the movement.

26 aug. 2026, 20:08 UTC

Aurinia Pharmaceuticals shares are lower amid broader Biotechnology sector weakness. A Form 4 filing revealed a $355,000 insider share sale by Chief Legal Officer Stephen P. Robertson.

25 aug. 2026, 19:36 UTC

Aurinia Pharmaceuticals Inc is trading higher amid a positive market environment, despite pulling back from earlier session highs. No specific news was identified.

24 aug. 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of declines observed over the past three sessions. No specific news was identified.

21 aug. 2026, 23:06 UTC

Aurinia Pharmaceuticals Inc. shares are higher in after-market hours, reflecting routine trading activity and maintaining a position above the 20-day moving average.

20 aug. 2026, 21:46 UTC

Aurinia Pharmaceuticals Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline.

19 aug. 2026, 23:02 UTC

Aurinia Pharmaceuticals settled patent litigation with Teva, securing exclusivity for voclosporin until December 2036. Shares rose in after-hours trading following the announcement.

18 aug. 2026, 19:56 UTC

Aurinia Pharmaceuticals Inc is trading higher today, though no specific news has been identified. Rising Treasury yields may pose challenges for equities.

17 aug. 2026, 20:02 UTC

Aurinia Pharmaceuticals shares are lower amid broader market declines and rising crude oil prices, despite some social media chatter about potential buyout interest.

14 aug. 2026, 19:26 UTC

Aurinia Pharmaceuticals shares are higher today, rebounding after earlier volatility amid broader market concerns over disappointing U.S. retail sales figures.

13 aug. 2026, 19:56 UTC

Aurinia Pharmaceuticals shares are lower today, despite ongoing sales growth of Lupkynis and a recent acquisition of Kezar Life Sciences.

11 aug. 2026, 20:06 UTC

Aurinia Pharmaceuticals Inc shares are trading lower today, continuing a trend of three consecutive daily declines amid no specific news to explain the movement.

10 aug. 2026, 20:06 UTC

Aurinia Pharmaceuticals shares decline following multiple downgrades from research firms, despite Royal Bank of Canada raising its price target to $16.00.

7 aug. 2026, 19:16 UTC

Aurinia Pharmaceuticals shares are lower today, despite earlier gains. RBC Capital raised the price target to $16.00 from $15.00, maintaining a Sector Perform rating.